1800 OWENS STREET, SAN FRANCISCO, CA
Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager for the Treatment of Solid Tumors
Shareholder votes
Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study
Provides Corporate Update and Reports First Quarter 2025 Financial Results
Annual Report to Security Holders
Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Changes in Board, Management or Compensation
Q2
FY 2023
Q3
Q1
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-1MEF
Correspondence
Submission Upload